Prevalence of anaemia and immunological markers among Ghanaian HAART-naïve HIV-patients and those on HAART

*Owiredu WKBA1*, Quaye L1, Amidu N2, Addai-Mensah O2

1. Department of Molecular Medicine, School of Medical Sciences, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
2. Department of Medical Laboratory Technology, Faculty of Allied Health Sciences, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana

Abstract

**Background:** Highly active antiretroviral therapy (HAART) for people living with HIV/AIDS (PLWHA) has been generally accepted as the gold standard for the management of HIV patients but conflicting reports about the ability of HAART to improve upon the quality of life of HIV patients has cast doubts over the efficacy and the need for therapy.

**Objective:** This study was conducted to assess the efficacy and ability of HAART to resolve immunological and haematological abnormalities in HIV infected patients, existent sex variations in immunological and haematological parameters and CD4 predictive ability of the study parameters.

**Methods:** A total of 442 PLWHA consisting of 166 patients on HAART (28 males and 138 females) and 276 HAART-naïve patients (76 males and 200 females) were recruited for this study. Complete haemogram, immunological analysis (CD4 & CD3) and weight were measured for all the patients.

**Results:** HAART patients were older and heavier than their naïve counterparts. The incidence of anaemia (Hb less or equal to 10.5 (63%) and PCV < 30% (37.6%)) and lymphopoenia (16.7%) in HAART-naïve patients was significantly higher compared to their counterparts on HAART (46%, 15.2% and 5.3%) respectively. 70% of HAART-naïve females had anaemia in comparison to 44% in HAART-naïve males (P = 0.0001). The likelihood of developing microcytic hypochromic anaemia in HAART-naïve patients was 5 times more compared to those on HAART (P = 0.0002). Total lymphocyte count, haemoglobin, lymphocyte count and weight were significant predictors of CD4 counts and TLC values between 1.0 – 2.0 kμL⁻¹ was a significant predictor of CD4 <200 cells mm⁻³.

**Conclusion:** HAART has the capability of reducing the incidence of anaemia and lymphopoenia which are associated with disease progression and death in HIV infected patients. Total lymphocyte count, haemoglobin and weight could also serve as useful predictive tools in the management and monitoring of HIV infected patients in resource limited settings.

**Key words:** Antiretroviral, Lymphocyte, TLC, CD4, WHO/ACTG

*Corresponding author:
Dr. William K.B.A. Owiredu
Department of Molecular Medicine
Kwame Nkrumah University of Science Technology
Kumasi, Ghana
Tel: +233 244 228 667
E-mail: wkbaowiredu@yahoo.com
Alternate E-mail: wkbaowiredu.sms@knust.edu.gh
the cytopoenia generally correlate to the stage of the
disease with anaemia being the most commonly
encountered haematologic abnormality and a
significant predictor of progression to AIDS or
death.8,9

The introduction of highly active antiretroviral
therapy (HAART) for treatment of HIV infection
has generally been accepted as the gold standard in
the management of HIV patients.9 Gea-Banacloche
and Lane,10 and Odunukwe et al.,9 reported
improvements in haematocrit and haemoglobin
values resulting in reduction in morbidity and
mortality of HIV patients and Omorugie et al.,11
reported no improvement in haematocrit values of
HAART treated HIV patients compared with
HAART-naïve patients in his study.

Against the background of such conflicting
reports which cast doubts on the efficacy and the
need for HAART in this HAART era, this study was
conducted to assess the impact of HAART in
resolving immunological and haematological
complications in HIV patients by comparatively
analysing the results (immunological and
haematological) of HAART-naïve patients and those
on HAART so as to establish the continual need of
HAART in the management of HIV patients.

Existent sex variations in the study parameters and
the ability of the study parameters to predict CD4
count and whether they can be used as surrogates
for CD4 in resource poor settings where assay
methods for viral loads and CD4 count are not
available were assessed.

Methods
Study area and design
This cross-sectional study was carried out at the
antiretroviral (ART) clinic in the Regional Hospital,
Bolgatanga which is located in the Upper East
Region of Ghana from September 2008 to
September 2009.

Study population
A total of 442 people living with HIV/AIDS
(PLWHA) and confirmed to be positive for HIV
(HIV-1, HIV-2 or both) visiting the ART clinic were
recruited for this study upon approval by the Clinical
Coordination and Research Development Board of
the hospital and obtaining written informed consent
from the patients. The study population consisted of
276 (76 males and 200 females) highly active
antiretroviral therapy (HAART) naïve patients and
166 (28 males and 138 females) patients who were
on HAART for a period of three (3) months or
more. HAART use was defined as receipt of two
nucleoside reverse transcriptase inhibitors (NRTI) and
one non-nucleoside reverse transcriptase inhibitor
(NNRTI) or one protease inhibitor (PI). Patients who
were pregnant and HAART-naïve patients who were
on medication (antibiotics, vitamin supplements and
tuberculosis treatment) at the time of sampling were
excluded from the study.

Sample collection and preparation
A volume of 5 ml of venous blood was collected
from each patient and dispensed into two vacutainer
ethylene diamine tetraacetic acid (EDTA) tubes (2
ml and 3 ml) respectively. The 2 ml sample was used
for immunological analysis (CD4/CD3 estimation)
and the 3 ml sample used for haematological analysis.

Immunological Assay
Absolute counts of CD4 and CD3 lymphocytes
were assayed using the BD FACSCOUNT system
(Becton Dickenson and Company, California, USA).

Haematological Assay
Haematological parameters: haemoglobin (Hb),
haematocrit (PCV), mean cell volume (MCV), mean
cell haemoglobin (MCH), mean cell haemoglobin
concentration (MCHC), red blood cell count (RBC),
red cell distribution width (RDW), white blood
cell count (WBC), lymphocyte count (LC), total
lymphocyte count (TLC), platelet count (PLT) and
mean platelet volume (MPV) were determined using
the automated blood analyzer Cell-Dyn 1800 (Abbott
Laboratories Diagnostics Division, USA).

Weight
Body weight was determined to the nearest 0.1kg in
light clothing with a bathroom scale (Zhongshan
Camry Electronics Co. Ltd. Guangdong, China).

Statistical Analysis
Results are presented as Means ± SEM. Unpaired t-
test was used to compare the means of all continuous
variables. Categorical data were analyzed using
Fisher’s exact test or χ² for trend. Linear regression
was used to test for the degree of association between
test parameters. A p-value of < 0.05 was considered
to be statistically significant. All statistical analyses
were done using GraphPad Prism version 5.0 for
windows (GraphPad software, San Diego California
USA, www.graphpad.com)

African Health Sciences Vol 11 No 1 March 2011
Results

Demographic characteristics and weight

Out of the 442 HIV/AIDS patients categorized into HAART-naïve and on HAART patients, majority of the HAART-naïve patients (88%) and those on HAART (83%) were within the age brackets of 20 – 49 years. Of the 276 HAART-naïve patients, 200 (72.5%) were females and 76 (27.5%) were males giving a female to male ratio of 3:1. Out of the 166 patients on HAART, 138 (83.1%) were females and 28 (16.9%) were males giving a female to male ratio of 5:1 (Table 4B). Patients on HAART were however older (36.91 ± 0.77 years, \( P < 0.01 \)) and heavier (54.92 ± 3.61 kg, \( P < 0.05 \)) than their HAART-naïve counterparts (33.42 ± 0.88 years; 48.93 ± 1.24 kg).

Females on HAART were significantly older (36.10 ± 0.85 years, \( P < 0.01 \)) when compared to those off HAART (32.17 ± 0.89 years) but there was no significant difference in the mean ages of male patients on HAART and those who were HAART-naïve (\( P > 0.05 \)) (Table 1). Furthermore, male patients on HAART were significantly heavier (75.50 ± 2.50 kg, \( P < 0.01 \)) than their HAART-naïve counterparts who were also heavier (54.08 ± 2.44 kg, \( P < 0.01 \)) when consequently compared with HAART-naïve females (47.00 ± 1.34 kg).

Anaemia, Packed Cell Volume (PCV) and Haemoglobin

Using packed cell volume (PCV) less than 30% as an indicator for anaemia, 37.6% (88/234) of the HAART-naïve patients were 3 times at risk of having reduced PCV compared to 15.2% (28/181) of the patients on HAART (\( P < 0.001 \)). The odds of PCV being reduced in both male and female patients on HAART compared to those off HAART was however not significant (\( P > 0.05 \)) (Table 4A) and the calculated mean PCV (35.68 ± 0.55%, \( P < 0.001 \)) in patients on HAART was significantly higher than that of patients who were HAART-naïve (32.64 ± 0.48%) (Table 1).

From Table 2, a further classification of the study population according to the World Health Organization/Aids Clinical Trial Group (WHO/ACTG) anaemia toxicity grades gave a 63% and 46% calculated incidence of anaemia (Hb ≤ 10.5 gDL\(^{-1}\)) in HAART-naïve patients and those on HAART respectively (\( X^2 = 10.68, P = 0.001 \)). Additionally, HAART-naïve patients are 3 times at risk of developing Grade 2 (\( P < 0.0001 \)) and Grade 3 anaemia (\( P = 0.0005 \)) compared to the patients on HAART. The odds of developing grades 2 and 3 anaemia in HAART-naïve females is 3 times more when compared to their counterparts on HAART (\( P < 0.0001 \)) and a comparison of males on HAART to their naïve counterparts in developing all four grades of anaemia did not show any significant difference (\( P > 0.05 \)). The calculated mean haemoglobin of (11.54 ± 0.33 g dL\(^{-1}\), \( P < 0.05 \)) and (10.33 ± 0.16 g dL\(^{-1}\), \( P < 0.001 \)) in men and females on HAART respectively were significantly higher when compared to their naïve counterparts (10.59 ± 0.29 g dL\(^{-1}\) and 9.45 ± 0.13 g dL\(^{-1}\)) but there was however no statistical significance between the mean haemoglobin values of patients on HAART and those who are HAART-naïve (\( P > 0.05 \)) (Table 1).

Table 1: General characteristic of the study population stratified by drug and gender

<table>
<thead>
<tr>
<th>Parameters</th>
<th>HIV Patients</th>
<th>Male Patients</th>
<th>Female Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HAART naïve</td>
<td>On HAART</td>
<td>HAART naïve</td>
</tr>
<tr>
<td>Age (yrs)</td>
<td>33.42 ± 0.88</td>
<td>36.91 ± 0.77**</td>
<td>36.68 ± 0.15</td>
</tr>
<tr>
<td>WT (kg)</td>
<td>48.93 ± 1.24</td>
<td>54.92 ± 3.61*</td>
<td>54.08 ± 2.44</td>
</tr>
<tr>
<td>CD4 (cell mm(^{-3}))</td>
<td>272.60 ± 13.24</td>
<td>315.30 ± 13.92*</td>
<td>251.60 ± 26.40</td>
</tr>
<tr>
<td>CD3 (cell mm(^{-3}))</td>
<td>1243.00 ± 43.55</td>
<td>1216.00 ± 45.19</td>
<td>272.60 ± 26.40</td>
</tr>
<tr>
<td>TWBC (x 10(^3) μl(^{-1}) )</td>
<td>5.19 ± 0.18</td>
<td>4.39 ± 0.12**</td>
<td>4.32 ± 0.24*</td>
</tr>
<tr>
<td>TLC (x 10(^3) μl(^{-1}) )</td>
<td>2.81 ± 0.09</td>
<td>2.73 ± 0.08</td>
<td>2.86 ± 0.21</td>
</tr>
<tr>
<td>LC (%)</td>
<td>55.48 ± 1.03</td>
<td>62.49 ± 1.00***</td>
<td>53.79 ± 2.18</td>
</tr>
<tr>
<td>RBC (x 10(^6) μl(^{-1}) )</td>
<td>3.55 ± 0.04</td>
<td>3.31 ± 0.05***</td>
<td>3.67 ± 0.11</td>
</tr>
<tr>
<td>HB (g dL(^{-1}) )</td>
<td>9.80 ± 0.12</td>
<td>10.59 ± 0.15</td>
<td>10.59 ± 0.29</td>
</tr>
</tbody>
</table>

African Health Sciences Vol 11 No 1 March 2011
Continuation of table 1

<table>
<thead>
<tr>
<th>Parameters</th>
<th>HIV Patients</th>
<th>Male Patients</th>
<th>Female Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HAART naïve</td>
<td>On HAART</td>
<td>HAART naïve</td>
</tr>
<tr>
<td>PCV (%)</td>
<td>32.64 ± 0.48</td>
<td>35.68 ± 0.55***</td>
<td>35.19 ± 1.19</td>
</tr>
<tr>
<td>MCV (fL)</td>
<td>93.02 ± 0.94</td>
<td>110.50 ± 1.33***</td>
<td>96.32 ± 2.30</td>
</tr>
<tr>
<td>MCH (pg)</td>
<td>27.92 ± 0.27</td>
<td>32.60 ± 0.50***</td>
<td>29.61 ± 0.66</td>
</tr>
<tr>
<td>MCHC (g dl⁻¹)</td>
<td>30.30 ± 0.25</td>
<td>29.66 ± 0.40</td>
<td>31.10 ± 0.65</td>
</tr>
<tr>
<td>RDW (%)</td>
<td>20.88 ± 0.50</td>
<td>18.64 ± 0.52</td>
<td>21.91 ± 1.39</td>
</tr>
<tr>
<td>PLT (x 10³ μl⁻¹)</td>
<td>174.40 ± 7.20</td>
<td>148.80 ± 6.07*</td>
<td>178.5 ± 18.82</td>
</tr>
<tr>
<td>MPV (fL)</td>
<td>11.25 ± 0.22</td>
<td>11.88 ± 0.20*</td>
<td>11.30 ± 0.48</td>
</tr>
</tbody>
</table>

Results are presented as means ± SEM. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 indicates the level of significance when the HAART naïve were compared to those on HAART (unpaired t-test); †P ≤ 0.05, ††P ≤ 0.01, †††P ≤ 0.001 indicates the level of significance when the male HAART naïve were compared to the male on HAART; §P ≤ 0.05, §§P ≤ 0.01, §§§P ≤ 0.001 indicates the level of significance when the female HAART naïve were compared to the female on HAART; ‡P ≤ 0.05, ‡‡P ≤ 0.01, ‡‡‡P ≤ 0.001 indicates the level of significance when the male HAART naïve were compared to the female HAART naïve; #P ≤ 0.05, ##P ≤ 0.01, ###P ≤ 0.001 indicates the level of significance when the male on HAART were compared to the female on HAART.

Type of anaemia
Using the mean cell volume (MCV) range of 80 – 96 fL and mean cell haemoglobin (MCH) range of 27 – 32 pg as pointers in distinguishing between the different types of anaemia where low MCV (<80 fL) is indicative of microcytosis, high MCV (>96 fL) indicates macrocytosis and low MCH (<27 pg) indicates hypochromia, HAART-naïve patients are 5 times at risk of developing microcytic hypochromic anaemia (P = 0.0002) in comparison to their counterparts on HAART and the relative risk of developing normocytic hypochromic (P = 0.0007) and normocytic normochromic anaemia (P = 0.0007) is 3 times more compared to the patients on HAART (Table 2). The same risk pattern, microcytic hypochromic (P = 0.0004), normocytic hypochromic (P = 0.0013) and normocytic normochromic (P = 0.0025) is observed in a comparative analysis of females on HAART to those who are HAART-naïve. A marginally significant risk of developing normocytic normochromic anaemia (P = 0.0485) was seen in male patients who are HAART-naïve compared to those on HAART but no significant differences were observed in the relative risk of developing macrocytic hypochromic anaemia in all the study populations (P > 0.05) (Table 2). From Table 1, calculated MCV values of (110.50 ± 1.33 fL, 112.5 ± 2.79 fL, 109.90 ± 1.51 fL; P ≤ 0.001) and MCH values of (32.60 ± 0.50 pg, 33.51 ± 0.81 pg, 32.35 ± 0.59 pg; P ≤ 0.001) in patients on HAART, males on HAART and females on HAART respectively were significantly higher compared to their naïve counterparts.

Leucopenia, Lymphopenia and Neutropoenia
Using a total white blood cell count (<2.5 k μL⁻¹), a lymphocyte count (<40%) and neutrophil count (<60%) as indicators of leucopenia, lymphopenia and neutropoenia respectively, there was no significant difference in the relative risk of developing leucopenia in all three study groups (P > 0.05) (Table 4A). The mean total white cell counts in patients on HAART (4.39 ± 0.12 k μL⁻¹, P < 0.01), males on HAART (4.32 ± 0.24 k μL⁻¹, P < 0.05) and females on HAART (4.41 ± 0.14 k μL⁻¹, P ≤ 0.05) were however significantly lower when compared to their naïve counterparts (5.19 ± 0.18 k μL⁻¹; 5.33 ± 0.41 k μL⁻¹ and 5.14 ± 0.23 k μL⁻¹) (Table 1). The calculated incidence of lymphopenia in HAART-naïve patients and those on HAART was 16.7% and 5.3% respectively and the difference in the proportion was significant (X² = 11.07, P = 0.0009). The relative risk of developing lymphopenia is 3 times in HAART-naïve patients (P = 0.0007) and 5 times more in HAART-naïve females (P = 0.0007) when compared to their counterparts on HAART. However, there was no significant difference in the odds of developing
lymphopenia when HAART-naïve males were compared to males on HAART (P > 0.05) (Table 4A). Significant increases in the mean lymphocyte counts of patients on HAART (62.49 ± 1.00%, P ≤ 0.001) and females on HAART (63.77 ± 1.05%, P ≤ 0.001) was observed when compared to their HAART-naïve counterparts. A comparative analysis of the mean lymphocyte value in males on HAART and HAART-naïve males showed no significant difference (P > 0.05) (Table 1).

There was no significant difference in the relative risk of developing neutropoenia in all three study populations (P > 0.05) (Table 4A).

Table 2: Study population stratified by anaemia, type of anaemia, CD4 counts, total lymphocyte count and drug use

<table>
<thead>
<tr>
<th>Parameters</th>
<th>HIV Patients</th>
<th>Male Patients</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HAARTNaïve</td>
<td>On HAART</td>
<td>OR(95% CI)</td>
<td>HAARTNaïve</td>
</tr>
<tr>
<td>WHO/ACTG Grade</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 1 (9.5-10.5)</td>
<td>51(20.1%)</td>
<td>39(25.8%)</td>
<td>0.7(0.5-1.2)</td>
<td>12(16.7%)</td>
</tr>
<tr>
<td>Grade 2 (8.0-9.4)</td>
<td>68(26.8%)</td>
<td>16(10.6%)</td>
<td>3.1(1.7-5.6)</td>
<td>12(16.7%)</td>
</tr>
<tr>
<td>Grade 3 (6.5-7.9)</td>
<td>33(13.0%)</td>
<td>9(6.0%)</td>
<td>2.4(1.1-5.1)</td>
<td>6(8.3%)</td>
</tr>
<tr>
<td>Grade 4 (&lt;6.5)</td>
<td>8(3.1%)</td>
<td>6(4.0%)</td>
<td>0.8(0.3-2.3)</td>
<td>2(2.8%)</td>
</tr>
<tr>
<td>Type of Anaemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Micro. Hypo.</td>
<td>34(14.5%)</td>
<td>5(3.3%)</td>
<td>5.0(1.9-13.0)</td>
<td>4(6.2%)</td>
</tr>
<tr>
<td>Macro. Hypo.</td>
<td>11(4.7%)</td>
<td>8(5.3%)</td>
<td>0.9(0.4-2.2)</td>
<td>2(3.1%)</td>
</tr>
<tr>
<td>Normo. Hypo.</td>
<td>46(19.7%)</td>
<td>11(7.3%)</td>
<td>3.1(1.6-6.2)</td>
<td>12(18.5%)</td>
</tr>
<tr>
<td>Normo. Normoc.</td>
<td>50(21.4%)</td>
<td>11(7.3%)</td>
<td>3.5(1.7-6.9)</td>
<td>15(23.1%)</td>
</tr>
<tr>
<td>CD4 (CDC)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-199</td>
<td>122(44.2%)</td>
<td>46(27.9%)</td>
<td>2.1(1.4-3.1)</td>
<td>39(50.0%)</td>
</tr>
<tr>
<td>200-499</td>
<td>112(40.6%)</td>
<td>94(56.6%)</td>
<td>0.5(0.4-2.2)</td>
<td>28(35.9%)</td>
</tr>
<tr>
<td>500+</td>
<td>42(15.2%)</td>
<td>26(15.7%)</td>
<td>1.0(0.6-1.6)</td>
<td>11(14.1%)</td>
</tr>
<tr>
<td>TLC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1.0</td>
<td>7(3.0%)</td>
<td>3(2.0%)</td>
<td>1.5(0.4-6.0)</td>
<td>4(6.2%)</td>
</tr>
<tr>
<td>1.0-2.0</td>
<td>77(32.9%)</td>
<td>39(25.8%)</td>
<td>1.4(0.9-2.2)</td>
<td>17(26.2%)</td>
</tr>
<tr>
<td>&gt;2.0</td>
<td>150(64.1%)</td>
<td>109(72.2%)</td>
<td>0.7(0.4-1.1)</td>
<td>44(67.7%)</td>
</tr>
</tbody>
</table>

*P ≤ 0.05, ***P ≤ 0.001 indicates the level of significance when the HAART naïve were compared to those on HAART (unpaired t-test); Micro. = microcytic; Hypo = hypochromic; Macro = macrocytic; Normoc. = normochromic HAART = Highly Active Antiretroviral Therapy; WHO/ACTG = World Health Organization/Aids Clinical Trial Group; OR = Odds Ratio; CD = Cluster of Differentiation; TLC = Total Lymphocyte count; CI = Confidence Interval.

CD4 counts

In Table 2, the Center for Disease Control (CDC) criteria was used to classify the study population into three categories based on CD4 counts: stage 1 (CD4 > 500 cells mm⁻³), stage 2 (CD4 between 200 – 499 cells mm⁻³) and stage 3 (CD4 <200 cells mm⁻³). The risk of having CD4 count <200 cells mm⁻³ is twice in HAART-naïve patients than those on HAART (P = 0.0006) and the chances of having CD4 count between 200 – 499 cells mm⁻³ is 2 times more in patients on HAART than those who are HAART-naïve (P = 0.0012). HAART-naïve females are 2.5 times at risk of having CD4 count <200 cells mm⁻³ when compared to their counterparts on HAART (P = 0.001) who have a twice better chance of developing CD4 counts between 200 – 499 cells mm⁻³ (P = 0.005). No significant difference was observed in the three categories of CD4 counts when males on HAART were compared to HAART-naïve males (P > 0.05) likewise with CD4 counts >500 cells mm⁻³ when patients on HAART and females on HAART were compared to their naïve counterparts. The mean CD4 count (315.30 ± 13.92 cells mm⁻³, P > 0.05) in patients on HAART is however greater when compared to that of patients
who are HAART-naïve (272.60 ± 13.24 cell mm⁻³) (Table 1).

**CD4 counts and TLC**

In a trend analysis of the three categories of CD4 counts and TLC in HAART-naïve patients (Table 3), when the TLC was between 1.0 – 2.0 k μL⁻¹, there was a gradual increase in the proportion of patients within the three CD4 categories from 8.3% in stage 1, 26.1% in stage 2 to a peak percentage of 46.5% within stage 3 (P < 0.0001). With a TLC > 2.0 k μL⁻¹, a steady decline in the proportion of patients within the three categories was seen with the highest percentage of 91.7% occurring within stage 1 (P < 0.0001). A gradual increase in the proportion of patients within the CD4 categories was observed with a peak proportion of 4% in stage 3 when the TLC was < 1.0 k μL⁻¹ but this was not statistically significant.

In patients on HAART, when the TLC was < 1.0 kμL⁻¹ and between 1.0 – 2.0 kμL⁻¹, there were gradual increases in the proportion of patients to the peak percentages of 7.3% (P = 0.0193) and 41.5% (P = 0.0008) respectively found in stage 3. However, when the TLC was > 2.0 kμL⁻¹, the proportional trend decreased steadily through the CD4 categories from 96.0% (P < 0.0001) in stage 1 through to 51.2% in stage 3.

**Table 3: Trend analysis of the study population stratified by drug use, TLC, anaemia and CD4 counts**

<table>
<thead>
<tr>
<th>Variables</th>
<th>Stage 3(0 - 199)</th>
<th>Stage 2(200 - 499)</th>
<th>Stage 1(≥500)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HAART Naïve</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TLC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1.0</td>
<td>4(4.0)</td>
<td>3(3.1)</td>
<td>0(0.0)</td>
<td>0.2713</td>
</tr>
<tr>
<td>1.0 - 2.0</td>
<td>47(46.5)</td>
<td>25(26.1)</td>
<td>3(8.3)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>&gt;2.0</td>
<td>50(49.5)</td>
<td>68(70.8)</td>
<td>33(91.7)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>Anaemia</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.5 - 10.5</td>
<td>20(18.2)</td>
<td>25(24.0)</td>
<td>6(15.4)</td>
<td>0.9454</td>
</tr>
<tr>
<td>8.0 - 9.4</td>
<td>32(29.1)</td>
<td>31(29.8)</td>
<td>5(12.8)</td>
<td>0.116</td>
</tr>
<tr>
<td>6.5 - 7.9</td>
<td>21(19.1)</td>
<td>9(8.7)</td>
<td>3(7.7)</td>
<td>0.0224</td>
</tr>
<tr>
<td>&lt;6.5</td>
<td>6(5.5)</td>
<td>2(1.9)</td>
<td>0(0.0)</td>
<td>0.0589</td>
</tr>
<tr>
<td><strong>On HAART</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TLC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1.0</td>
<td>3(7.3)</td>
<td>0(0.0)</td>
<td>0(0.0)</td>
<td>0.0193</td>
</tr>
<tr>
<td>1.0 - 2.0</td>
<td>17(41.5)</td>
<td>20(25.3)</td>
<td>1(4.0)</td>
<td>0.0008</td>
</tr>
<tr>
<td>&gt;2.0</td>
<td>21(51.2)</td>
<td>59(74.7)</td>
<td>24(96.0)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>Anaemia</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.5 - 10.5</td>
<td>15(36.6)</td>
<td>20(25.3)</td>
<td>2(8.0)</td>
<td>0.0107</td>
</tr>
<tr>
<td>8.0 - 9.4</td>
<td>4(9.8)</td>
<td>7(8.9)</td>
<td>4(16.0)</td>
<td>0.4977</td>
</tr>
<tr>
<td>6.5 - 7.9</td>
<td>5(12.2)</td>
<td>3(3.8)</td>
<td>1(4.0)</td>
<td>0.12</td>
</tr>
<tr>
<td>&lt;6.5</td>
<td>2(4.9)</td>
<td>4(5.1)</td>
<td>0(0.0)</td>
<td>0.4019</td>
</tr>
</tbody>
</table>

CD = Cluster of Differentiation; HAART = Highly Active Antiretroviral; TLC = Total Lymphocyte Count
CD4 counts and anaemia
Comparing the four grades of anaemia to the three categories of CD4 for trend (Table 3), a gradual increase in the proportion of HAART-naïve patients within the three CD4 categories was observed with peak proportion of 19.1% in stage 3 developing grade 3 anaemia (P = 0.0224) and 5.5% developing grade 4 anaemia (P = 0.0589). 36.6% of the patients on HAART within stage 3 CD4 count had grade 1 anaemia (P = 0.0107). No significant trend was however observed between grades 2, 3, 4 anaemia and the CD4 stages (P > 0.05).

Thrombocytopenia
Using a platelet count (<150 k μL⁻¹) as an indicator for thrombocytopenia in Table 4A, there was no significant difference in the odds of developing thrombocytopenia in all the three study populations (P > 0.05). However the calculated mean platelet counts (148.80 ± 6.07 k μL⁻¹, P ≤ 0.05) in patients on HAART and (144.90 ± 6.69 k μL⁻¹, P ≤ 0.01) in females on HAART were significantly lower compared to their naïve counterparts. Consequently, no significant difference was observed in the mean platelet count when males on HAART were compared to those who are HAART-naïve (P > 0.05).

Table 4A: Cytopoenic tendency in the study population

<table>
<thead>
<tr>
<th>Parameters</th>
<th>HIV Patients</th>
<th>Male Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HAART</td>
<td>On HAART</td>
</tr>
<tr>
<td></td>
<td>Naïve</td>
<td>(95%CI)</td>
</tr>
<tr>
<td>TWBC (&lt; 2.5 k/μL)</td>
<td>18(7.7)</td>
<td>9(6.0)</td>
</tr>
<tr>
<td>LYM (&lt; 40%)</td>
<td>39(16.7)</td>
<td>8(5.3)**</td>
</tr>
<tr>
<td>Neut (&lt; 60%)</td>
<td>225(96.2)</td>
<td>150(99.3)</td>
</tr>
<tr>
<td>TLC (&lt; 1.2 k/μL)</td>
<td>16(6.8)</td>
<td>6(4.0)</td>
</tr>
<tr>
<td>PCV (&lt; 30%)</td>
<td>88(37.6)</td>
<td>23(15.2)**</td>
</tr>
<tr>
<td>PLT (&lt; 150 k/μL)</td>
<td>118(50.4)</td>
<td>78(51.7)</td>
</tr>
</tbody>
</table>

*P ≤ 0.05, ***P ≤ 0.001 indicates the level of significance when HAART-naïve were compared to those on HAART (unpaired t-test); TWBC = Total white blood cell count; LYM = Lymphocyte; Neut = Neutrophil; TLC = Total lymphocyte count; PCV = Packed cell volume; PLT = Platelet.

Table 4B: Age and sex distribution of the study population

<table>
<thead>
<tr>
<th></th>
<th>HAART-Naïve</th>
<th>On HAART</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>N = 276; (n/N)</td>
<td>N = 166; (n/N)</td>
</tr>
<tr>
<td>0-9</td>
<td>10(3.6)</td>
<td>0(0.0)</td>
</tr>
<tr>
<td>10-19</td>
<td>5(1.8)</td>
<td>2(1.2)</td>
</tr>
<tr>
<td>20-29</td>
<td>78(28.3)</td>
<td>28(16.0)</td>
</tr>
<tr>
<td>30-39</td>
<td>108(39.1)</td>
<td>76(44.5)</td>
</tr>
<tr>
<td>40-49</td>
<td>57(20.7)</td>
<td>40(22.8)</td>
</tr>
<tr>
<td>50-59</td>
<td>10(3.6)</td>
<td>18(10.3)</td>
</tr>
<tr>
<td>60-69</td>
<td>5(1.8)</td>
<td>2(1.2)</td>
</tr>
<tr>
<td>&gt;70</td>
<td>3(1.1)</td>
<td>0(0.0)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>76(27.5)</td>
<td>28(16.9)</td>
</tr>
<tr>
<td>Female</td>
<td>200(72.5)</td>
<td>138(83.1)</td>
</tr>
</tbody>
</table>
Predictive parameters for CD4 counts

Figure 1 shows linear regression graphs of some selected haematological parameters and weight in HAART-naïve patients against CD4 counts in order to test for their ability to predict CD4 counts. For every cell $\mu L^{-1}$ increase in TLC ($r^2 = 0.07$, $P < 0.0001$), a percent increase in lymphocyte count ($r^2 = 0.12$, $P < 0.0001$), a g dL$^{-1}$ increase in haemoglobin ($r^2 = 0.10$, $P < 0.0001$) and a kg increase in weight ($r^2 = 0.04$, $P = 0.0041$), there was a mean increase of 0.002, 0.025, 0.003 and 0.009 cells mm$^{-3}$ in the CD4 count. Platelet count showed a negative relationship with CD4 count ($\hat{a} = -0.057$, $r^2 = 0.013$, $P = 0.0827$) and TWBC showed no significant association with CD4 ($\hat{a} = 0.000$, $r^2 = 0.00$, $P = 0.3379$).

Figure 1: Regression line graphs between total white blood cell (TWBC), total lymphocyte count (TLC), Lymphocyte count, Haemoglobin, Platelet, Weight and CD4 counts of HAART naïve subjects

A related regression analysis conducted in patients on HAART with the same study predictors showed that, for every cell $\mu L^{-1}$ increases in TWBC ($r^2 = 0.13$, $P < 0.0001$) and TLC ($r^2 = 0.18$, $P < 0.0001$), a percent rise in lymphocyte count ($r^2 = 0.08$, $P = 0.0007$), a g dL$^{-1}$ rise in haemoglobin ($r^2 = 0.06$, $P = 0.0026$) and a kg increase weight ($r^2 = 0.05$, $P = 0.0314$), mean increase of 0.003, 0.002, 0.019, 0.002, and 0.012 cells mm$^{-3}$ in the CD4 count was observed. There was no significant linear relationship between platelet count and CD4 count ($\hat{a} = 0.015$, $r^2 = 0.00$, $P = 0.6654$) (Figure 2).
Figure 2: Regression line graphs between total white blood count (TWBC), total lymphocyte count (TLC), Lymphocyte count, Haemoglobin, Platelet, Weight and CD4 counts in subjects on HAART

Discussion

Haematological manifestations have been documented to be the second most common cause of morbidity and mortality in HIV patients. Amballie et al., conducted a study to identify haematological parameters which could serve as pointers to the diagnosis of HIV/AIDS in resource poor settings and Odunukwe et al., reported the use of haematological response for monitoring patients on highly active antiretroviral therapy (HAART) in resource poor settings in view of the fact that the cost of diagnostic and monitoring techniques for HIV/AIDS are unaffordable to most people in resource poor settings. Due to the general acceptability of HAART as the gold standard in the treatment of HIV patients, establishing the presence of abnormal haematological manifestations in HAART-naïve HIV patients and those on HAART and performing a comparative analysis within the two study groups will give a clear pointer to the overall impact of the treatment regimen in HIV patients.

Demographics and HIV infection

In this study, about 86% (88% of HAART-naïve patients and 83% of patients on HAART) of the study population fell within the 20 – 49 years age brackets which is known to be the sexually active age group with highest peak percentage observed within the 30 – 39 age groups for both sexes. Amornkul et al., reported a 25 – 29 years peak age for females and 30 – 34 years peak age for males. This means that heterosexual contact may probably contribute to a greater proportion of HIV infections in our study group and this finding is buttressed by the Ghana Aids Commission report which states that heterosexual intercourse accounts for 75 to 80 percent of all HIV/AIDS infections. Amballie et al., in their study on people living with HIV/AIDS
reported a percentage of 75 within this age bracket. Females formed about 76% of the study population and a further finding of female to male ratio of 3:1 in HAART-naïve patients and 5:1 in patients on HAART strongly suggests that females are at a greater risk of getting infected with HIV than men and this could happen at an early stage in their lives probably early to mid thirties considering the significant differences in the mean ages of HAART-naïve males to HAART-naïve females (36.68 ± 2.15 and 32.17 ± 0.89; P < 0.05). The World Health Organization (WHO) reported that HIV/AIDS affects females most severely in sub-Saharan Africa and women of reproductive age make up almost 57% of adults living with HIV, accounting for up to 80% of HIV infected women in the world. The significant difference in age between patients on HAART and HAART-naïve patients further supports the proposition that HIV/AIDS infection may be acquired at an early age and most probably during the reproductive stage of life. The strict eligibility criteria for qualifying for HAART (WHO recommendation of CD4 <350 cells mm⁻³, WHO stages I, II and III HIV disease with CD4 <200 cells mm⁻³, WHO stage IV HIV disease (clinical AIDS) irrespective of CD4, WHO stage II HIV disease with TLC less than 1200 cells mm⁻³) may also explain why most of the patients on HAART appear to be older than their naïve counterparts in that there could be a time lag between the time a patient tests positive for HIV and the time treatment is initiated and treatment once started is continued throughout the life of the patient.

Wood et al., reported inadequate nutrient intake among a large proportion of HIV patients and Ogunibuje et al., reported that there is evidence to show that nutritional intervention assists in maintaining and optimizing nutritional status and immune function, prevents the development of nutritional deficiency, loss of weight and lean body mass, promotes response to medical treatment and increases longevity in HIV patients. The improvement in the weight of patients on HAART, males on HAART and females on HAART over their naïve counterparts observed in this study could be a direct consequence of strict adherence to counselling which insists on good nutritional status alongside drug therapy. Bouic et al., and Ogunibuje et al., reported that nutritional supplementation can decrease viral load and through this intervention therefore, HAART might improve upon the quality of life of an HIV patient.

Anaemia and HAART

From this study, HAART-naïve patients have a high risk of developing reduced PCV compared to their counterparts on HAART. Furthermore, HAART-naïve patients and HAART-naïve females have a higher risk of developing moderate to severe anaemia compared to their counterparts on HAART and the calculated mean haemoglobin values in males and females on HAART were significantly higher compared to their naïve counterparts. As related in the studies conducted by Moore et al., Mocroft et al., and Levine et al., the improvement in haemoglobin levels could be due to increase in the proportion of erythrocytes in relation to total blood volume as a result of elevated PCV. The reduced incidence of anaemia, the reduced risk of developing moderate to severe anaemia, the overall improvement in PCV and haemoglobin concentration when on HAART in this study confirms the effectiveness of HAART in improving the quality of life of HIV patients. Belperio & Rhew and Odunukwe et al., reported improved haematocrit values, increased haemoglobin concentration and decreased prevalence of anaemia in their study which is in agreement with our studies and Abrams et al., reported that small increases in haemoglobin level (up to 2 g dL⁻¹) were associated with a beneficial effect on total quality of life. The calculated incidence of anaemia by sex was 50% in females on HAART and 70% in HAART-naïve females compared to 34% and 44% in males on and off HAART respectively. The difference in proportion of HAART-naïve females to HAART-naïve males was statistically significant (X² = 14.8, P = 0.0001) showing that HIV infected females in this study are more at risk of developing anaemia compared to infected males. Levine et al., reported a similar finding in their study and attributed it to sex and race whereas Volberding et al., attributed it to menstrual blood loss in women and to the drains on iron stores that occur with pregnancy and delivery. This finding is however in sharp contrast to the findings of a study conducted by Omoregie et al., which reported high prevalence of anaemia in HAART-naïve males compared to their female counterparts. The absence of a significant difference in the proportion of females on HAART to males on HAART (X² = 2.34, P = 0.1257) further buttresses the ability of HAART to improve upon the severity of anaemia in females.

Type of anaemia and HAART
The relatively high risk of developing microcytic hypochromic anaemia found in HAART-naïve patients and HAART-naïve females compared to those on HAART in this study reflects the overall nutritional deficiencies (malnutrition and malabsorption) associated with HIV patients. Blood loss and drains on iron stores that occur with pregnancy and delivery in HIV infected women could be an added consequence of anaemia in females especially since microcytic anaemia is associated with iron deficiency. The high risk of developing the other types of anaemia (normocytic hypochromic, normocytic normochromic and macrocytic hypochromic) in HAART-naïve patients in this study can be attributed to the multifactorial aetiology of anaemia as related in the study conducted by Volberding et al., (2004) where causes of anaemia were associated to blood loss or decreased red blood cell (RBC) production, increased RBC destruction and ineffective RBC production.

The odds of developing macrocytic hypochromic anaemia was the same in all the study populations and did not differ significantly (Table 2) but the average MCV for patients on HAART, males on HAART and females on HAART (Table 1) were significantly higher compared to their naïve counterparts. Moyle 7 reported that elevated MCV (macrocytosis) is typically associated with vitamin B12 or folate deficiency and in the setting of HIV treatment reflects the use of zidovudine (AZT) or stavudine (d4T). The elevated MCV observed in patients on HAART in this study could therefore be attributed to drug usage since most of them had a combination therapy of either AZT or d4T with lamivudine (3TC) but other factors will come into play considering the fact that HAART-naïve patients had a similar likelihood of developing macrocytosis compared to those on HAART. The absolute lymphocyte counts gave a marginally significant indication of lymphopenia when HAART-naïve females were compared to their counterparts on HAART whilst the differential count gave a stronger indication. On a gender comparison therefore, HIV infected females will probably have a faster progression in the depletion of lymphocytes than infected males.

A further observation of significant increments in the mean differential lymphocyte counts in patients on HAART and females on HAART over their naïve counterparts gives proof that the observed lymphopenia may have been corrected and improved upon by an intervention (HAART usage). The mean absolute counts gave no such findings in all the study populations. Differential lymphocyte counts may therefore serve as a useful tool in indicating lymphopenia and improvements in lymphocyte counts in HIV infected patients than absolute counts. Significant reductions in the total white blood cell counts when the study population on HAART were compared to their naïve counterparts and could be due to the broad myelosuppressive effects of the drug regimen mostly associated with AZT usage.

African Health Sciences Vol 11 No 1 March 2011
and females are at greater risk of having CD4 < 200 cells mm⁻³ in comparison to their counterparts on HAART who are better placed to have greater improvements in their CD4 counts to levels within 200 – 499 cells mm⁻³. It was further observed that CD4 counts <200 cells mm⁻³ was strongly associated with severe anaemia (Grades 3 & 4) in HAART-naïve patients and could lead to rapid disease progression and decreased survival as related in the study conducted by Obirikorang & Yeboah 37 and Curkendall et al., 38. When on HAART however, a high proportion of the patients with CD4 <200 cells mm⁻³ had a better chance of falling within the Grade 1(9.5 – 10.5 g dL⁻¹) anaemia toxicity range. The significant finding of the ability of HAART to improve upon CD4 counts and anaemia in HIV infected patients in this study proves the ability of HAART to reduce morbidity and mortality in HIV infection as related in the study of Gea-Banacloche & Lane, 10. The ability of HAART to improve upon CD4 counts and anaemia observed in this study can be attributed to the effectiveness of HAART in reducing viral replication and viral load as related in the studies of Belperio & Rhew 26 and Odunukwe et al., 9.

Thrombocytopenia and HAART

Although the relative risk of developing thrombocytopenia in all the study populations was the same, the mean platelet counts of patients on HAART and females on HAART was significantly lower compared to their naïve counterparts meaning that we are likely to find lower platelet counts in patients and females on HAART than in HIV infected patients. HAART though effective in improving on haematocrit and decreasing the prevalence of anaemia could lead to a decrease in platelet counts. This finding is in sharp contrast to that of Attili et al., 39 where thrombocytopenic incidence of 4.8% in HIV patients was reported and their platelet counts increased after antiretroviral therapy. An incidence of about 50% was calculated in both HAART-naïve and patients on HAART which almost agrees with the findings of the study conducted by Pechere et al., 40 who reported a thrombocytopenic incidence of 40%.

Parameters that can predict CD4

A linear regression model was conducted to assess the ability of some selected study parameters to predict CD4 counts in HAART-naïve patients and those on HAART. In HAART-naïve patients, it was observed that for unit increases in CD4 as an independent variable, there were corresponding unit increases in TLC, lymphocyte count, haemoglobin and weight. There was no linear relationship between total white blood cell count and CD4 count and platelet count showed a negative relationship. However in patients on HAART, there was a positive relationship between total white blood cell count and CD4 counts and platelet count gave a non-linear relationship with CD4 counts. TLC, lymphocyte count, haemoglobin and weight still gave positive relationships with CD4. The ability of TLC, lymphocyte count, haemoglobin and weight to predict CD4 count in both HAART-naïve patients and those on HAART suggests that these parameters which are relatively inexpensive and easily available compared to techniques for assaying CD4 and viral load could serve as accurate tools that can be used for monitoring the patients’ immune status during therapy in addition to determining when patients should start antiretroviral therapy. Mwamburi et al., 41 reported a similar finding and suggested modification of the models to suit specific needs for use in underserved areas.

TLC and CD4

The value of TLC as a surrogate for CD4 in monitoring HIV disease in the absence of viral loads and CD4 counts has been argued 42-44 but current WHO guidelines only commit to using TLC in conjunction with clinical data as a criterion to initiate HAART in resource poor settings 19. A trend analysis to find the ability of TLC to predict CD4 < 200 cells mm⁻³ was conducted and it was observed that with a TLC of 1.0 – 2.0 kμL⁻¹, a greater proportion of the HAART-naïve patients had CD4 counts <200 cells mm⁻³ and TLC >2.0 kμL⁻¹ was associated with a peak proportion of patients with CD4 >500 cells mm⁻³. The same trend was observed in patients on HAART. A range of TLC cut-offs have been used and reported as predictors of CD4 <200 cells mm⁻³ and these range from 1.0 kμL⁻¹ with a specificity of 98% and a sensitivity of 53% to 1.4 kμL⁻¹ with a sensitivity of 73% and a specificity of 88% 45, 46. Our study shows that a TLC range of 1.0 – 2.0 kμL⁻¹ could predict CD4 <200 cells mm⁻³ but this will serve a better purpose in the management and monitoring of HIV patients if a calibration cut-off could be established in our settings. The calibration cut-off in addition to clinical data (haemoglobin, weight, lymphocyte count) could serve as useful models in resource poor setting.
Conclusion

This study has shown that HAART usage is effective in decreasing the prevalence of anaemia by improving upon haematocrit and haemoglobin values and this positive impact leads to increased survival in people living with HIV/AIDS. Furthermore there was a positive impact on lymphocyte count and improvements in CD4 counts to values ≥ 200 cells mm⁻³ was observed when on HAART. TLC, Lymphocyte count, haemoglobin and weight were good predictors of CD4 counts and as such may serve as useful tools in the monitoring and management of HIV patients in resource poor settings considering the fact that they are easier and cheaper to perform than techniques for assaying CD4 counts and viral load. TLC could further predict CD4 counts ≥ 200 cells mm⁻³ and this could add to the strength of the study predictors when time insensitive methods are used in the care and management of HIV patients. Necessary efforts should therefore be taken to scale up therapy in this HAART era particularly in resource poor settings. The study further revealed that females in their reproductive age are at a greater risk of getting infected than males and this could perpetuate documented social complications associated with HIV infection. Continued efforts on educating the citizenry (targeted by age group) on social lifestyle and possible risk factors associated with HIV infection should still be emphasized considering the dire implications of new infections on the social fabric.

References


